News
Ipsen and its fellow French partner Genfit are competing with Intercept and Advanz’s Ocaliva, which was approved in 2016 and ...
1d
Zacks Investment Research on MSNHere's Why Gilead Sciences (GILD) is a Strong Value StockIt doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...
2d
Zacks Investment Research on MSNGilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings GrowthThe market expects Gilead Sciences (GILD) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...
3d
US Weekly on MSNWhat to Know About ‘The Handmaid’s Tale’ Spinoff ‘The Testaments’: Returning Cast Members and MoreHulu's spinoff of 'The Handmaid's Tale' titled 'The Testaments' comes after the original show's sixth and final season ...
The Handmaid’s Tale Season 6 finale is just a few weeks away, but fans hoping for a neatly wrapped story to June Osbourne and ...
Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...
On The Handmaid's Tale Season 6 Episode 4 Joseph gets a promotion for his reforms while the resistance plans a major assault ...
As the final season of "The Handmaid's Tale" begins today, we're taking a look back on everything to know about the hit Hulu ...
"It's not about a relationship she chose, like with Fred," Bruce Miller says, explaining why writers chose to introduce the ...
The resistance against Gilead carries on. Here's what you need to remember before "The Handmaid's Tale" Season 6 starts.
Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results